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Statement of Problem –  The objective of this study is to understand conditional risk factors for Clostridium 
difficile infection (CDI) over time and between hospitals   
Methods –  Retrospective cohort of patients admitted to five adult hospitals in the Baltimore/Washington DC area in 
calendar year 2016 and 2017. International Statistical Classification of Diseases and Related Health Problems (ICD) 
10 codes, the Premier’s CareScienceTM Mortality Risk Score, room and clinical data were obtained through Premier 
CareScience reports and EPIC electronic medical record reports. Days of therapy (DOT) for antibiotics, probiotic 
supplementation and proton pump inhibitor use (PPI) were cumulative through each day of hospitalization. 
Colonization pressure was calculated as days of exposure multiplied by the number of patients with CDI in a unit 
that month. A multivariable logistic regression was performed for each day of admission separately and for each 
hospital.  
Results – There were 1922 (1.0%) cases of CDI among 192,522 patients. The Premier’s CareScienceTM Mortality 
Risk Score expected mortality score was the greatest contributor to risk of CDI particularly in the first 5 days of 
hospitalization. Probiotic supplementation exposure was a significant risk factor in the first (OR 2.67) and third day 
(OR 1.46) of the hospital course. ICU exposure was protective with 37-33% lower odds of CDI on day 1 and 2 but 
by day 8 and 11 became a significant risk factor for CDI (OR 1.15, OR 1.12). Colonization pressure risk decreased 
over time, but remained significant for the first 8 days of admission (OR 1.19-OR 1.03). Carbapenem, penicillin, 
cephalosporin, quinolone and other antibiotic use was a risk factor for CDI however the conditional risk decreased 
over time. Clindamycin was protective in our cohort.  
The Premier’s CareScienceTM Mortality Risk Score was the greatest predictor for CDI in 4/5 hospitals (OR 6-30).  
Colonization pressure was a significant risk factor for CDI in three hospitals. Carbapenem use was a risk factor in 
two hospitals and cephalosporin use was only a risk factor in one hospital. 
Conclusions – Risk factors for CDI vary over time and by hospital and interventions to prevent CDI need to be 
tailored by hospital and time to be effective. 
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Clostridium difficile epidemiology and burden of disease 
Clostridium difficile is the most common healthcare-associated infection complicating 1% of all hospital admissions 
and accounting for 30,000 deaths in the US annually 1 2 3. Clostridium difficile infection (CDI) occurs through a 
complex pathophysiology which includes environmental exposure and microbiome disruption through antibiotic use 
4 5. Host factors such as comorbid conditions and advanced age, also play a role in the risk for infection 4 5. Up to 
80% of these infections may be preventable, however our understanding of the relative importance of various risk 
factors over time in the development of infection is limited 6.  
Risk factors  
Antibiotic exposures 
Antibiotic exposure is a known risk factor for CDI.  
Different classes of antibiotic have different risks of colonization and infection with Clostridium difficile. The most 
strongly associated classes of antibiotics include second, third and fourth generation cephalosporins, clindamycin, 
carbapenems, trimethoprim/sulphamethoxazole, fluoroquinolones and penicillin combinations 7. Unfortunately, 
most of these data are limited in that only two studies attempted to match or adjust for patient severity of illness, and 
only a few matched for time at risk and there was considerable heterogeneity in the patient populations studied 7 8. 
None of the studies adequately address time varying exposures 7. In evaluating only randomized controlled trials, 
where confounding by patient severity would be minimized, carbapenem use was associated with a higher rate of 
CDI compared to fluoroquinolone use and cephalosporin use was associated with a higher rate of CDI than 
penicillin and fluoroquinolone use. Clindamycin use was associated with a higher rate of CDI compared to 
cephalosporin and penicillin use primarily in outpatients 9. Some antibiotics may be more associated with 
colonization. Tigecycline and doxycycline appear to be protective for CDI and colonization with Clostridium 
difficile 10 . One study compared patients who received carbapenem vs tigecycline in which every case of hospital 
onset diarrhea was evaluated for clostridium difficile and weekly rectal swabs were performed for carbapenem-
resistant Enterobacteriaceae (CRE) and found that patients who received tigecycline were less likely to be colonized 
with Clostridium difficile but equally likely to be colonized with CRE as compared to patients who received 
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meropenem 11. Decreasing antibiotic usage in hospital settings through antimicrobial stewardship should reduce 
rates of CDI. A recent meta-analysis reviewing studies of antimicrobial stewardship on CDI rates found that there 
was a 32% reduction in CDI cases with the implementation of an antibiotic stewardship program 12. These results 
can be variable as several recent single center studies have shown that reducing antibiotic usage did not decrease the 
rate of hospital onset CDI 13 14.  
Confounding is a significant concern in studies looking at the association between antibiotics and CDI. Many factors 
have been associated with CDI including specific antidepressants and histamine antagonists 15 16. While some of 
these medications may have biologic plausibility by causing microbiome disruption, some may simply be 
confounded correlations, 
Environmental exposure and colonization pressure 
Colonization with Clostridium difficile is necessary for infection to occur.  
Four to 15 percent of patients that are admitted to the hospital are already colonized with Clostridium difficile  and 
colonized patients have a 6 fold increased risk of developing infection 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 . Since 
only 0.5% of the community is colonized with Clostridium difficile and history of recent hospitalization is more 
strongly associated with Clostridium difficile colonization compared to even previous antibiotic use acquisition most 
likely occurs in hospital settings 33 18. Ten to twenty percent of hospitalized patients become colonized during their 
hospitalization 23 19 32,34 
Hospital environments are often colonized with Clostridium difficile spores. One gram of stool in a patient with CDI 
has 100 million spores and patients with active CDI contaminate 20-51% of surfaces in their rooms  35 36 37 38 39 40 41 
42 43,44 45 46 47 19 48. Most worrisome is that even asymptomatic patients colonize 7-33% of environmental surfaces in 
their room. There is clinical evidence of transmission in that roommates and previous room occupants who have 
CDI or have been exposed to antibiotics have been associated with higher rates of CDI 49 50 51 52 27. Interestingly, 
ward level antibiotic prescribing is a risk factor for CDI independent of patient characteristics and individual 
antibiotic prescriptions 53. In studies looking at various risk factors for CDI, exposure to the hospital environment 
and colonization pressure seem to be the factors with the greatest effect size 54 13 55.  
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Genotype testing with multilocus variable number of tandem repeats analysis (MLVA) and whole genomic 
sequencing have shown that 6-30% of cases of CDI are associated with asymptomatic carriers 27.   
Hospital variation   
It is likely that different hospitals have varying risk factors for CDI due to the different populations they serve and 
facility design and subsequent transmission risk. One study using whole genomic sequencing of Clostridium difficile 
infection found that the percentage of cases that can be attributed to transmission varies between hospitals 56 
Epidemiologic methods 
The majority of studies investigating risk factors for CDI assess overall risk factors for hospitalization and do not 
incorporate time-varying exposures which are critical in understanding acute exposures and short durations of risk 
57. Conditional risk refers to the subsequent risk of acquiring an event if you have survived a certain duration 
without the event. An example of the importance of differentiating overall risk from conditional risk can be seen by 
comparing overall relapse rates among patients with testicular cancer vs the conditional relapse rate among patients 
who survived the first two years without a relapse 58. This is important for healthcare-associated infections like CDI 
where one event influences the next event. This type of analysis also allows us to un-confound length of stay with 
risk for infection.  
Objectives 
We sought to understand the conditional risk of CDI over time across a health system and to account for clustering 
through a colonization pressure metric.  
APPROACH/METHODS 
Population 
The population consists of adult patients admitted to one of 5 acute care hospitals within a health system in 
Maryland and/or Washington DC between January 1, 2016 and December 31, 2017.  The hospitals included one 
quaternary care hospital (1,100 beds), one tertiary care hospital (426 beds) and three community hospitals (220-320 
beds). All five hospitals have medicine and surgical beds and the two academic hospitals have specialty units 




We performed a retrospective cohort study of all adult inpatients admitted in five hospitals within a health system  
Clinical care 
The clinical care of patents are similar among all five hospitals. All five hospitals have the same antibiotic formulary 
and all have antibiotic stewardship teams to minimize unnecessary antibiotic usage. Probiotic prescriptions were left 
to the discretion of the clinician until 2017, when it was no longer prescribed by the health system. One hospital 
used a protocol to prescribe probiotics on all patients receiving antibiotics for one year of the study period. 
Definitions 
Antibiotic days, proton pump inhibitor (PPI) days and probiotic days were measured as days of therapy (DOT). For 
antibiotics, the DOT was calculated for each class of antibiotic separately, thus a patient receiving two different 
antibiotic classes would be counted separately for each class. Premier’s CareScienceTM Mortality Risk Score, a 
proprietary calculated risk adjustment score ranging from 0-1 was obtained through Premier (Premier Healthcare 
Solutions, Inc, Charlotte, NC) 59. Patients were identified as having CDI based on a positive Clostridium difficile 
nucleic acid amplification test (NAAT) documented in the electronic medical record (EMR). Patients were followed 
until they (a) had a positive Clostridium difficile NAAT test, (b) were discharged or (c) were administratively 
censored at 30 days after the date of admission. Only the first episode of CDI was included. Those who did not 
experience CDI by the end of follow-up were considered non-cases. Colonization pressure was calculated as number 
of cases of CDI cases in a particular patient care unit in a month times the number of days the patient spent in that 
unit. Units were categorized as intensive care units (ICU) or non ICU. These data sets were combined using the 
hospital admission record number.  
Statistical Analysis:  
Patient demographics and clinical parameters were compared among those with CDI and those who did not develop 
CDI during their hospitalization using Chi-square or two-sample t test as appropriate. We reported means with 
standard deviation for continuous variables and frequencies for categorical variables. We performed an overall 
multivariable logistic regression using variables known to be risks for CDI. In order to better understand the 
conditional risk of infection, we analyzed risk factors for CDI by day of admission separately for each day, 1-14, of 
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hospitalizations. Days of therapy (DOT) for antibiotics, probiotics and PPI were cumulative up until each day of 
hospitalization. Patients who developed CDI, died or were discharged prior to the day of analysis were excluded 
from the risk set for the following day. Additionally a separate multivariable logistic regression was performed for 
each hospital separately. 
We report adjusted odds ratio with p values. The analysis was conducted using Stata Version 15.0 (StataCorp, 
College Station, Texas) statistical software. 
RESULTS: 
There were 192,522 patients included in the analysis with 1922 (1.0%) cases of CDI. The characteristics of patients 
with and without CDI are summarized in Table 1. The non-cumulative incidence of infection by day varied from 
12/10,000 patients to 27/10,000 patients (Graph 1). Patient age, female sex, Premier CareScienceTM Expected 
Mortality score, probiotic use, ICU stay and carbapenem, cephalosporin, penicillin and other antimicrobial use were 
higher among patients with CDI. Clindamycin use was lower among patients with CDI.  
In the overall multivariable logistic regression, age (OR 1.015 p=<0.0001), Premier CareScienceTM Expected 
Mortality score (OR 7.158 (OR 1.015 p=<0.0001), colonization pressure per one person/day unit of exposure (OR 
1.010, p=<0.0001), ICU exposure by day (OR 1.026, p=<0.0001) and carbapenem use (OR 1.035 p =0.017), were 
associated with increased odds of CDI. Proton pump inhibitor use (0.950, p=<0.0001), clindamycin use (OR 0.781 
p<0.0001) and treating facility other than the reference facility was associated with lower odds of CDI (Table 2). 
The AUR for the overall model was 0.77. 
In assessing conditional risk factors over time, the expected mortality score, a surrogate marker for patient’s baseline 
comorbidities and illness, was the greatest contributor to risk of CDI particularly in the first 5 days of hospitalization 
(Table 3,Graph 2). Probiotic exposure was a significant risk factor in the first (OR 2.67) and third day (OR 1.46) of 
the hospital course (Table 3, Graph 3). ICU exposure was initially protective with 37-33% lower odds of CDI on day 
1 and 2 but by day 8 and 11 became a significant risk factor for CDI (OR 1.15, OR 1.12). Colonization pressure per 
1 person/day of exposure decreased over time, but remained a significant risk factor over the first 8 days of 
admission (OR 1.19-OR 1.03) (Table 3, Graph 4). Carbapenem, penicillin, cephalosporin, quinolone and other 
antibiotic use was a risk factor for CDI. Interestingly, for these antibiotic classes, the conditional risk decreased over 
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time (Table 3, Graph 5). Surprisingly, clindamycin, an antibiotic known to increase risk of CDI, was protective in 
our cohort. Hospital facility was also independently associated with risk of CDI. Hospital 3, a community hospital, 
was associated with an increased risk of CDI on the first day of admission and then subsequently was associated 
with a reduced risk for CDI.   
Risk factors for hospital onset CDI (CDI diagnosed on or after day 4 or admission) by facility varied by facility. For 
4/5 hospitals, the Premier’s CareScienceTM Mortality Risk Score was the greatest predictor for CDI with an odds 
ratio between 6 and 29. Colonization pressure was a significant risk factor for CDI in two hospitals. Carbapenem 
use, a very broad-spectrum class of antibiotic, was only a risk factor in two hospitals and cephalosporin use was only 
a risk factor in one hospital (Table 4). 
Discussion 
Our study demonstrates that many of the known risk factors for CDI vary in their relative importance over time and 
that factors that are important early in hospital stay are not as important later in the hospital course. This was most 
notable for antibiotic exposure. The impact of carbapenem exposure and quinolone antibiotic exposure as a risk 
factor for CDI decreased over the first few days of hospitalization, suggesting that not starting antibiotic treatment 
may be more important than shortening treatment for these antibiotics. Our data is consistent with data from Barnes-
Jewish hospital where cephalosporin, quinolone or intravenous vancomycin for less than 7 days was not associated 
with CDI risk 55 Interestingly, clindamycin was protective for CDI in our cohort, which is different from other 
studies which focused mostly on community-onset CDI 60 61 9 62. In hospitalized patients, clindamycin exposure has 
been variably associated with development of CDI 63 7 64 65. 
Probiotic exposure was a risk factor for CDI early in the hospital course. Proton pump inhibitor (PPI) exposure has 
been associated with CDI risk in some studies and not associated with CDI in other studies 5. In our study PPI 
exposure was not associated with an increased risk for CDI, except for hospital day 10.  
Understanding time-varying exposures and conditional risk is important for focusing interventions where they will 
have the greatest impact. This is seen in device-associated infections, where the risk of central-line associated 
bloodstream infections increase over time. While this makes intuitive sense for device-associated infections, where 
there is an incremental risk of infection based on duration of line placement, this is less well understood for CDI 66 67 
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68 69 70 71. Most of the previous studies assessing risk factors for CDI look only at the overall composite risk which 
does not allow for time-varying risks which we have now shown to be important.   
Limitations 
The limitations of our study are the relatively low number of cases of CDI over time which reduces the power to 
detect risk factors that may be important later in the hospital course. While we attempted to include a variety of 
practice settings, there may be regional differences that limit generalizability. We used the Premier CareScienceTM 
Expected Mortality score to adjust for differences in baseline health, however we are not able to adjust for severity 
of illness during hospitalization.  
Public health significance 
CDI causes 30,000 deaths annually in the US and hospital-onset CDI increases cost of care by $1.5 billion dollars a 
year 5.  Hospital onset Clostridium difficile infection can be prevented in up to 80% of cases according to modeling 
studies 6. Understanding specific risk factors over time in hospitalized patients will enable interventions to reduce 
the incidence of these infections. 
Recommendations/Next steps 
Our study highlights the importance of understanding risk factors for CDI over time and between hospitals. Several 
interesting findings deserve further evaluation. The association of probiotics with CDI particularly early in the 
hospital course was an unexpected finding. Next steps would be to review a random sample of charts of patients on 
probiotics to see if these patients had a previous history of CDI that was not captured by testing at JHHS as this may 
have confounded the association.  
While our models had good predictive ability, they were incomplete. The next steps would be to use machine 
learning methods such as random forrest on additional data from the EMR to detect patterns that may better predict 








Table 1 Characteristics of Patients by Clostridium difficile infection 
    
Factor CDI = 0 CDI = 1 p-value 
Total number of patients 191887 1917 
 
Age, mean (SD) 53.5 (23.3) 61.8 (19.5) <0.001 
Gender    
 
     Male 82906 (43.2%) 891 (46.5%) 0.016 
     Female  108980 (56.8%) 1026 (53.5%) 
 
Mortality    
     Alive 185213 (98.0%) 1757 (93.2%) <0.001 
     Died 3771 (2.0%) 129 (6.8%) 
 
Facility    
     Hospital 1 34744 (18.1%) 166 (8.7%) <0.001 
     Hospital 2 33862 (17.6%) 369 (19.2%) 
 
     Hospital 3 20346 (10.6%) 134 (7.0%) 
 
     Hospital 4 24397 (12.7%) 358 (18.7%) 
 
     Hospital 5 78538 (40.9%) 890 (46.4%) 
 
Premier predicted mortality score (0-1) 0.0 (0.1) 0.1 (0.2) <0.001 
PPI mean DOT (SD) 1.7 (3.6) 1.6 (3.4) 0.41 
Probiotic, mean DOT (SD) 0.1 (0.9) 0.1 (0.9) 0.007 
Colonization pressure mean (SD)  2.1 (6.8) 3.6 (8.4) <0.001 
ICU stay, mean days (SD) 0.5 (2.1) 1.0 (2.8) <0.001 
Antibiotic class DOT     
     Aminogylcoside, mean DOT (SD) 0.1 (0.6) 0.1 (0.5) 0.21 
     Carbapenem, mean DOT (SD) 0.2 (1.1) 0.3 (1.3) <0.001 
     Cephalosporin, mean DOT (SD) 1.1 (2.3) 1.3 (2.4) 0.012 
     Clindamycin, mean DOT (SD) 0.1 (0.8) 0.1 (0.4) <0.001 
     PCN, mean DOT (SD) 0.7 (2.3) 1.1 (2.3) <0.001 
     Quinolone, mean DOT (SD) 0.3 (1.3) 0.3 (1.1) 0.21 
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Table 2 – Overall risk factors for Clostridium difficile infection – multivariable logistic regression 
Factor OR p-value 
Age,  1.015 0.000 
Gender    
     Female 1.015 0.755 
     Male  (ref)  
Facility   
     Hospital 1 (ref)  
     Hospital 2 0.817 0.002 
     Hospital 3 0.382 <0.0001 
     Hospital 4 0.860 0.026 
     Hospital 5 0.506 <0.0001 
Premier predicted mortality score (0-1) 7.158 <0.0001 
PPI DOT  0.950 <0.0001 
Probiotic, DOT  1.038 0.057 
Colonization pressure (1 exposure day) 1.010 <0.0001 
ICU stay, days  1.026 0.003 
Antibiotic class DOT    
     Aminogylcoside, DOT  0.967 0.479 
     Carbapenem, DOT  1.035 0.017 
     Cephalosporin, DOT  0.986 0.173 
     Clindamycin, DOT  0.781 <0.0001 
     PCN, DOT  1.014 0.114 
     Quinolone, DOT  0.991 0.595 























Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14
odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio
VARIABLES (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE) (SE)
Age 1.013*** 1.009*** 1.010** 1.003 1.006 1.008 1.014 1.005 1.009 1.010 1.010 1.026** 1.025 1.005
(0.002) (0.003) (0.004) (0.005) (0.006) (0.007) (0.008) (0.008) (0.010) (0.009) (0.010) (0.012) (0.015) (0.015)
Female 1.078 0.987 1.295 1.079 1.495** 0.882 1.324 1.313 1.219 0.799 0.856 0.974 0.912 1.568
(0.097) (0.098) (0.195) (0.196) (0.300) (0.199) (0.338) (0.354) (0.388) (0.233) (0.276) (0.334) (0.386) (0.787)
Hospital facility
Hospital 1 (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref) (ref)
Hospital 2 1.293** 0.808 0.851 0.941 1.196 0.898 0.679 0.822 1.220 1.369 0.923 0.195** 1.088 1.079
(0.165) (0.109) (0.167) (0.241) (0.293) (0.260) (0.276) (0.301) (0.533) (0.551) (0.402) (0.147) (0.605) (0.685)
Hospital 3 0.782 0.485*** 0.331*** 0.741 0.173*** 0.283** 0.460 0.138 0.613 1.419 0.231 0.133 0.228 0.222
(0.121) (0.083) (0.091) (0.214) (0.103) (0.151) (0.250) (0.141) (0.389) (0.649) (0.239) (0.138) (0.240) (0.257)
Hospital 4 2.089*** 0.637*** 0.441*** 0.792 0.906 0.427** 1.518 1.037 0.869 1.753 1.512 0.472 0.288 -
(0.253) (0.101) (0.109) (0.225) (0.270) (0.184) (0.544) (0.426) (0.500) (0.762) (0.682) (0.280) (0.306)
Hospital 5 1.221 0.499*** 0.347*** 0.463 0.286** 0.514 1.067 1.150 2.058 0.420 0.449 0.346 - -
(0.190) (0.102) (0.112) (0.186) (0.173) (0.293) (0.598) (0.666) (1.203) (0.450) (0.488) (0.310)
Premier Expected Mortality Score 4.702*** 3.487*** 6.617*** 3.094** 1.001 6.054*** 1.827 1.615 1.171 2.629 0.937 1.533 3.286 8.695**
(1.196) (1.143) (2.777) (1.753) (0.742) (3.248) (1.440) (1.144) (1.130) (1.798) (0.785) (1.349) (2.942) (8.290)
Proton Pump Inhibitor - 0.884 0.919 0.911 1.050 0.920 1.022 1.047 0.966 1.079** 0.982 0.961 0.967 0.982
(0.122) (0.096) (0.075) (0.064) (0.054) (0.052) (0.049) (0.048) (0.041) (0.039) (0.038) (0.043) (0.046)
Probiotics - 2.669*** 1.607 1.457** 0.889 1.134 0.871 0.946 0.802 1.064 0.986 1.18 - 1.399***
(0.890) (0.396) (0.245) (0.236) (0.211) (0.178) (0.172) (0.213) (0.122) (0.161) (0.108) (0.113)
Colonization pressure - 1.190*** 1.116*** 1.082*** 1.070*** 1.042*** 1.040*** 1.031** 0.998 1.014 1.019 1.014 0.968 0.995
(0.023) (0.024) (0.020) (0.015) (0.017) (0.015) (0.014) (0.021) (0.014) (0.012) (0.014) (0.030) (0.023)
ICU days - 0.626*** 0.674*** 0.996 1.027 1.084 0.956 1.149** 1.028 1.033 1.119** 1.065 1.051 1.003
(0.111) (0.099) (0.102) (0.083) (0.076) (0.073) (0.063) (0.066) (0.051) (0.050) (0.052) (0.057) (0.062)
Aminoglycosides - 0.327 0.265 1.425 0.986 1.092 1.254 1.042 0.862 1.040 0.765 0.678 0.810 0.923
(0.232) (0.249) (0.343) (0.300) (0.270) (0.219) (0.244) (0.321) (0.182) (0.313) (0.452) (0.414) (0.262)
Carbapenem - 2.047*** 1.809*** 1.457*** 1.459*** 1.115 1.171 1.140 1.197** 1.237*** 1.181** 1.044 0.902 1.069
(0.498) (0.318) (0.210) (0.161) (0.134) (0.115) (0.116) (0.107) (0.076) (0.081) (0.099) (0.161) (0.111)
Cephalosporin - 0.835 1.154 1.195** 1.149** 1.019 1.042 1.055 1.053 1.105** 1.096 1.079 1.089 1.083
(0.088) (0.100) (0.089) (0.078) (0.068) (0.066) (0.066) (0.070) (0.055) (0.056) (0.057) (0.065) (0.069)
Clindamycin - 0.160*** 0.528 0.426 0.817 1.039 0.558 1.108 - 0.956 0.977 0.949 - 1.027
(0.093) (0.198) (0.194) (0.192) (0.166) (0.281) (0.146) (0.163) (0.160) (0.179) (0.165)
Penicillins - 1.224 1.701*** 1.292*** 1.311*** 1.008 1.045 1.170*** 1.131** 1.024 1.030 1.066 1.094 1.049
(0.171) (0.156) (0.102) (0.085) (0.072) (0.066) (0.060) (0.063) (0.054) (0.053) (0.050) (0.056) (0.063)
Quinolone - 1.662*** 1.502*** 1.488*** 0.919 1.179 0.881 0.927 0.884 1.020 1.035 1.097 1.203*** 0.957
(0.297) (0.230) (0.166) (0.161) (0.118) (0.132) (0.132) (0.143) (0.094) (0.096) (0.079) (0.077) (0.125)
Other antibiotic - 1.889*** 1.127 1.073 0.931 1.023 1.042 0.943 0.988 0.959 0.997 0.981 0.988 0.974
(0.131) (0.071) (0.055) (0.049) (0.042) (0.038) (0.042) (0.039) (0.034) (0.030) (0.032) (0.035) (0.038)
Cases 525 423 187 125 105 81 64 56 41 49 40 35 23 17
Observations 179,823 175,479 146,615 106,993 77,051 57,063 44,363 35,250 26,132 23,131 19,345 16,405 12,244 10,691
Infection Rate (Per 10,000 Patient Days) 29.20 24.11 12.75 11.68 13.63 14.19 14.43 15.89 15.69 21.18 20.68 21.33 18.78 15.90
seEform in parentheses
*** p<0.01, ** p<0.05
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Age 1.01 1.01 1.01 1.00 1.01 1.01 1.01 1.01 1.01 1.01 1.01 1.03 1.03 1.01
Female 1.08 0.99 1.30 1.08 1.50 0.88 1.32 1.31 1.22 0.80 0.86 0.97 0.91 1.57












Age Female Premier Expected Mortality Score
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Table 4 – Risk factors for CDI by hospital  
 
 
Overall  Hospital 1 Hospital 2 Hospital 3 Hospital 4 Hospital 5
VARIABLES odds ratio odds ratio odds ratio odds ratio odds ratio odds ratio
Age 1.009*** 1.012*** 1.005 1.009 0.999 1.029***
(0.002) (0.003) (0.005) (0.008) (0.006) (0.011)
1.Female 0.924 1.021 1.074 1.142 0.702* 0.394**










MortalityExpectedCSStd 7.726*** 7.193*** 6.680*** 3.940 13.349*** 29.918***
(1.416) (1.918) (2.468) (3.663) (5.421) (33.518)
Proton pump inhibitor use 0.985 0.983 0.992 0.985 0.995 0.969
(0.008) (0.011) (0.019) (0.044) (0.024) (0.059)
Probiotic 1.062** 1.006 1.074 1.048 1.142*** 0.911
(0.025) (0.108) (0.074) (0.074) (0.046) (0.076)
Colonization pressure (person/day) 1.013*** 1.014*** 1.01 1.035** 1.016** 1.016
(0.003) (0.005) (0.006) (0.018) (0.008) (0.031)
ICU day 1.026** 1.008 1.04 1.111 1.031 0.942
(0.011) (0.017) (0.022) (0.066) (0.025) (0.082)
Aminoglycoside (per DOT) 1.012 0.999 1.060 1.131 0.729 1.046
(0.051) (0.068) (0.095) (0.192) (0.373) (0.364)
Carbapenem (per DOT) 1.054*** 1.027 1.040 1.094 1.096** 1.204**
(0.019) (0.028) (0.042) (0.087) (0.045) (0.103)
Cephalosporin (per DOT) 1.045*** 1.070*** 0.984 1.021 0.969 1.015
(0.013) (0.015) (0.035) (0.073) (0.043) (0.125)
Clindamycin (per DOT) 0.902 0.822 0.921 1.090 0.889 1.201
(0.065) (0.104) (0.113) (0.307) (0.169) (0.344)
Other antibiotic (per DOT) 0.994 0.987 1.016 0.947 1.055*** 0.992
(0.006) (0.008) (0.016) (0.056) (0.018) (0.055)
Penicil l in (per DOT) 1.030** 1.024 1.043 1.002 1.019 1.144**
(0.012) (0.015) (0.029) (0.067) (0.032) (0.076)
Quinolone (per DOT) 0.992 1.019 0.947 0.956 0.900 0.780
(0.023) (0.027) (0.068) (0.116) (0.079) (0.195)
Observations 106,993 46,851 17,922 16,617 14,116 11,487
seEform in parentheses
*** p<0.01, ** p<0.05,
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2016 Lecturer “Outbreak Investigation” S Society for Healthcare Epidemiology of America (SHEA) fellows 
course  – National 
 
2016 Lecturer “Saturday Night with the Pager” Society for Healthcare Epidemiology of America (SHEA) 
fellows course – National 
 
2018 Moderator - Society for Healthcare Epidemiology of America (SHEA) Annual meeting 
 




2015 Lecturer and curriculum development “Hospital Epidemiology Summer Course” Tel Aviv University 




Pre-doctoral Advisees /Mentees  
 
2012 Alexandra Thomas, MPH, capstone Advisor - Infectious Disease Society of America abstract 
2015-2017 Morgan Katz, MD – mentorship in hospital epidemiology 
2017 Saranya Seetharaman, MBBS MPH - Capstone Advisor  
2018 Arti Gharpure MPH - Capstone Advisor 
2018 Donna Phantran MPH – Capstone Advisor 
 
 
Educational Program Building / Leadership  
 
2002-2007 - Associate Program Director Internal Medicine Residency – Albert Einstein Medical Center 
2002-2007 - Student Clerkship Site Director Internal Medical – Jefferson Medical School 
2002-2007 - Physical Diagnosis Site Course Director affiliate site - Jefferson Medical School  
2016-2017 - Course Co-director Healthcare Epidemiology – Johns Hopkins School of Public Health 
2018 – present - Society of Healthcare Epidemiology of America - SHEA/CDC Track Vice Chair 
 
 




SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES  
 
System Innovation Focus –In 2001, I was tasked with developing an antibiotic stewardship program at 
AEMC. We were able to build local support for this program and save over $100,000 in antibiotic costs in the 
first year of implementation. I moved to Abington Memorial Hospital in 2007 as the hospital epidemiologist 
and in my first year Pennsylvania was the first state to enact mandatory public reporting for healthcare 
associated infections and require implementation of an infection control software. Within 6 months we 
successfully implemented all of these requirements. I moved to Johns Hopkins Bayview Medical Center in 
2011 and at the time we had one of the highest central line associated bloodstream infection rate in the state. 
Now after a series of rapid interventions we have the lowest rate among academic hospitals in the state.  
 
System Innovation and Quality Improvement efforts within JHMI: 
 




 Reduction in CLABSI – 200% in 3 years 
 Reduction in craniotomy infections – 30% in 4 years 
 Hand Hygiene compliance - > 88% - in 2 years 
 Reduction in C section infection rates – 50% - in 2 years 
 
System Innovation and Quality Improvement efforts outside of JHMI: 
 
2014 – Assessment of MERS coronavirus preparedness at multiple hospitals in Saudi Arabia in conjunction 
with Aramco 
 
2015 - Development of an Infection Prevention Program for the prevention of MERS Coronavirus, National 
Guard Hospital, Saudi Arabia 
 
2017 – Infection Control Assessment JHAH  
 
ORGANIZATIONAL ACTIVITIES  
 
Institutional Administrative Appointments  
 
2013-current – Co-chair, Surgical Site Infection prevention group (SSIP) 
 
Journal peer review activities    
 
2011-2016 reviewer e-Plasty  
2011 present – reviewer BMC Infectious Diseases  
2016 reviewer American Journal of Infection control 
2017 reviewer Infection Control and Hospital Epidemiology 
2018 reviewer Journal of Infection Prevention 
 
Other peer review activities  
 
2016 -2018 Infectious Disease Society of America abstract reviewer  
 
Advisory Committees, Review Groups/Study Sections 
 
2015 Maryland Health Care Commission Healthcare Advisory Committee 
2016 Educational Committee Panel - Society of Healthcare Epidemiologists of America/CDC outbreak 
response training program  
2016 The National Academies of Sciences, Engineering, and Medicine - presenter N95 and FXX surgical 
masks 
2016 FDA Advisory Panel – Wound dressings 
2016 Society of Healthcare Epidemiology of America/Center for Disease Control Outbreak Response 
Training Program   
2017 Society of Healthcare Epidemiology of America Education Committee Member 
2017 Society of Healthcare Epidemiology of America Policy Committee Member 
2018 Society of Healthcare Epidemiology of America Planning Committee 
2018 The National Academies of Sciences, Engineering, and Medicine – member - Committee on Personal 
Protective Equipment for Workplace Safety and Health  
2018 Council for Outbreak Response: Healthcare-Associated Infections and Antimicrobial Resistant 
Pathogens (COHRA) – Centers for Disease Control and Council for State and Territorial Epidemiologists  
 
Professional Societies  
 
2007 – current  - member, Society of Healthcare Epidemiology Association  
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Awards, Honors  
 
2015 Armstrong Award for Excellence in Quality and Safety 
2016 Medical Staff Award – HEIC team Johns Hopkins Bayview Medical Center 





2013 Asahi Memorial Hospital, Japan – Visiting professor.  
2016 Washington State Healthcare Advisory Board – CLABSI Reduction in high risk environments 
 
 
 
